Fornix’s allergy drug found effective in Phase II/III hayfever study
The results show that the highest of the three doses of Oralgen grass pollen covered by the study can bring about a substantial decrease in allergic complaints even
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.